On September 10, 2020 Mustang Bio, Inc. ("Mustang") (NASDAQ: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors and rare genetic diseases, reported that Manuel Litchman, M.D., President and Chief Executive Officer, will participate in three virtual investor conferences in September 2020 (Press release, Mustang Bio, SEP 10, 2020, View Source [SID1234564961]). The company will also host virtual one-on-one meetings during the conferences.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Details of the events are as follows:

H.C. Wainwright 22nd Annual Global Investment Conference: Presentation on Monday, September 14, 2020, at 2:30 p.m. EDT
Cantor Virtual Global Healthcare Conference: Fireside Chat on Wednesday, September 16, 2020, at 2:00 p.m. EDT
Oppenheimer Fall Healthcare Life Sciences & MedTech Summit: Fireside Chat on Monday, September 21, 2020, at 3:20 p.m. EDT
Live webcasts of the presentation and fireside chats will be available on the Events page of the Investors Relations section of Mustang’s website: www.mustangbio.com. Archived replays of the webcasts will be available for approximately 30 days following each presentation and fireside chat.